Written question asked by Lord Hunt of Kings Heath (Labour) on Monday, 7 June 2021, in the House of Lords. It was due for an answer on Monday, 21 June 2021. It was answered by Lord Bethell (Conservative) on Tuesday, 22 June 2021 on behalf of the Department of Health and Social Care.
NHS: Drugs
- Question
-
To ask Her Majesty's Government what steps they are taking to ensure medicines licensed by the Medicines and Healthcare products Regulatory Agency (MHRA), through Oribis and the Innovative Licensing and Access Pathway (ILAP), are promptly reimbursed by the NHS.
- Answer
-
The National Institute for Health and Care Excellence (NICE) is committed to publishing draft guidance on new medicines at the time of licensing, with final guidance published within three months of licensing wherever possible. The Medicines and Healthcare products Regulatory Agency, NICE and NHS England and NHS Improvement are working together to ensure that there is an integrated, timely approach to supporting access for National Health Service patients to products licensed through Project Orbis and the Innovative Licensing and Access Pathway. Interim access arrangements may be considered where NICE’s guidance is not anticipated to be published in line with the three month timeframe.
Secondary information
- Type
- Written question
- Reference
- HL753
- Session
- 2021-22
- Subjects
- Licensing Drugs NHS Medicines and Healthcare products Regulatory Agency
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2021-07-21 11:28:53 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/lords/2021-22/HL753
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/lords/2021-22/HL753
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/lords/2021-22/HL753